See Asa at Microbiome & Probiotic R&D & Business Collaboration Forum - La Jolla, California 10/13/2025
October 4, 2023 By: Asa Waldstein

Blog Claims Result in Warning Letter

Takeaway -

Blogs are marketing statements

This warning letter cites a kratom company for making disease claims related to opioid withdrawal, cancer, and depression in blogs.

The learning targets in this Warning Letter Wednesday are:

1) Blogs are marketing claims

2) Comparing products to drugs is high risk

3) Scan websites for high-risk statements

Blogs are marketing claims. Blogs continue to be cited in warning letters as they are “active” pieces of marketing, even if they are several years old. In this warning letter, the company talks about kava, an ingredient in its products being used for ADHD. If their products did not contain kava, this is low risk, but since this blog promotes its ingredients, this is essentially the same as putting “Our products help ADHD” right on the label.

From warning letter (blog): “Here are ten amazing kava benefits you should be aware of . . . May Alleviate ADHD Symptoms[,] kava may be beneficial to people who suffer from attention deficit hyperactivity disorder (ADHD).”

Comparing product benefits to drugs is a great way to attract FDA attention. The example below is ultra-high risk because FDA is likely concerned that if people think the product works the same as cancer drugs, the consumer may forego lifesaving treatments for the natural (unproven) options. I am a fan of natural products, but it’s important to market them in a compliant manner that does not inadvertently give people false hope about their uses.

From warning letter: “Two of Kava’s constituents …. have similar potency to the Alzheimer’s disease treatment Memantine.”

I write more about the risks of comparing products to drugs.

Most of the claims referenced in this letter have been removed, but there still are many claims on their website. I ran Apex Compliance and found dozens of very high-risk statements, especially when discussing their ingredient’s benefits. There are also statements about helping COVID symptoms on their “forgotten” blog posts. I developed Apex Compliance to help companies identify and remove marketing risks on their websites and content before publishing. Learn more and schedule a demo.

Also, DM me to schedule an Apex Compliance meeting at SupplySide West!

Read the full warning letter here.

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Cannabis Committee, helping shape policy and industry best practices